Fluticasone Propionate Cream Rx
Generic Name and Formulations:
Fluticasone propionate 0.05%.
Various generic manufacturers
Indications for Fluticasone Propionate Cream:
Adults and Children:
<3mos: not established. ≥3mos: apply a thin film to affected areas twice daily; atopic dermatitis: 1–2 times daily. Discontinue when control is achieved (max 4 weeks in children). Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Avoid tight-fitting diapers or plastic pants. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Lotion: avoid excessive sun exposure. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, pruritus, irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, miliaria, erythema, dry skin, excoriation; HPA axis suppression (esp. in children).
Formerly known under the brand name Cutivate.
Crm, oint—contact supplier; Lotion—120mL
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL